On May 7, 2025, Health and Global Policy Institute (HGPI) released a new set of policy recommendations “Better Use of Cost-effectiveness Evaluation for Pharmaceuticals in Japan”

These recommendations are being released as a part of a project “HGPI Expert Policy Advocacy Platform,” which will facilitate the creation and promotion of policy recommendations by HGPI fellows and others associated with the Institute. Through this platform, policy recommendations developed by HGPI Fellows and others are scrutinized and approved by a review committee within HGPI. Upon their approval, HGPI commits to issuing and advocating for the proposals. We hope that this new platform will produce a wide variety of both feasible and creative solutions to today’s pressing health policy issues.

For the second phase of the project, we have set the theme “Better Use of Cost-effectiveness Evaluation for Pharmaceuticals in Japan,”. Dr. Ataru Igarashi will explain the content of the policy recommendations in our upcoming seminar. In this seminar, Dr Igarashi will discuss the necessary human resources for more effective evaluation and how to present the results based on Japan’s characteristics from international comparisons of ‘cost-effectiveness evaluation’ for pharmaceuticals.

[Event Overview]

• Speaker:
  Dr. Ataru Igarashi (HGPI Fellow/ Project Associate Professor, Graduate School of Pharmaceutical Sciences, The University of Tokyo/ Visiting Associate Professor, Graduate School of Data Science, Yokohama City University)
• Date & Time: Tuesday, May 20, 2025; 18:00-19:30 JST
• Format: Online (Zoom webinar)
• Language: Japanese
• Participation Fee: Free
• Capacity: 500 participants

■Profile:

Ataru Igarashi (HGPI Fellow/ Project Associate Professor, Graduate School of Pharmaceutical Sciences, The University of Tokyo/ Visiting Associate Professor, Graduate School of Data Science, Yokohama City University)

Ataru IGARASHI, Ph.D., is an associate professor at Yokohama City University School of Medicine, Unit of Public Health and Preventive Medicine. In 2002, he graduated from the Faculty of Pharmaceutical Sciences, The University of Tokyo. He started his career at The University of Tokyo as an assistant professor just after he received his Ph.D. degree in 2008. His areas of expertise are health economics and pharmacoeconomics. His research on vaccination policy, anti-smoking policy and pharmacoeconomics have been used in legislative decision-making process.